Disclosed are novel isoflavone derivatives having the structure of Formula I: which are ALDH-2 inhibitors useful for treating a patient in need thereof for dependence upon drugs of addiction for example addiction to dopamine-producing agent such as cocaine morphine amphetamines nicotine and alcohol.

A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli Klebsiella pneumoniae Klebsiella oxytoca Pseudomonas aeruginosa Haemophilus influenzae Proteus mirabilis Enterobacter species Serratia marcescens as well as those caused by Burkholderia cepacia Stenotrophomonas maltophilia Alcaligenes xylosoxidans and multidrug resistant Pseudomonas aeruginosa using a concentrated formulation o...

±-Aztreonam lysinate is able to be administered via inhalation. It is useful in the treatment of pulmonary bacterial infections particularly gram-negative bacterial infections.

The invention is related to methods of inhibiting hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse surgical intervention viral hepatitis the ingestion of hepatotoxic drugs or other hepatic diseases. The invention also relates to pharmaceutical compositions for use in the method.

The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate Viread�) and (2R 5S cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-13-oxathiolan-5-yl)-(1H)-pyrimidin-2-one(emtricitabine Emtriva(TM) (-)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections including infections with HIV mutants bearing resist...

Disclosed is a synthesis suitable for large scale manufacture of an A

±-Aztreonam lysinate is able to be administered via inhalation. It is useful in the treatment of pulmonary bacterial infections particularly gram-negative bacterial infections.

Aztreonam lysinate is able to be administered via inhalation. It is useful in the treatment of pulmonary bacterial infections particularly gram-negative bacterial infections. Preparation of aztreonam lysinate using ��-aztreonam provides an advantageous manufacturing process and a product which has high purity and stability.

Disclosed are novel compounds having the structure of Formula (I): which are useful for treating a human for dependence upon substances of addiction for example addiction to a dopamine-producing agent such as cocaine morphine amphetamines nicotine and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.